Menopause, Laughter Therapy, and Well-Being

What this trial studies

The intervention will be conducted by Assist. Prof. Dr. Nurten ÖZÇALKAP.

Conditions in scope

• Therapy
• Menopause
• Sleep
• Psychological Well-being
• Women

Interventions

• grup 1 laughter yoga therapy (Other) — Participants received a total of 8 sessions of laughter yoga therapy, conducted twice weekly.

Who can join

Women only · Adults (Child, Adult, Older Adult) · Accepts healthy volunteers.

Inclusion criteria

• Willingness to participate in the study
• Ability to communicate
• Having entered menopause within the last 3 years
• Having experienced natural menopause
• Being literate

Exclusion criteria

• Having undergone surgical menopause
• Having a serious psychiatric or neurological disorder (e.g., schizophrenia, bipolar disorder, dementia, epilepsy)
• Having a chronic disease that may significantly affect overall quality of life and cognitive functions
• Having a physical condition that prevents participation in laughter therapy sessions (e.g., respiratory distress, vertigo, incontinence, severe cardiac disease)
• Using antidepressants or engaging in other non-pharmacological methods to reduce stress
• Receiving hormone replacement therapy
• Having experienced a traumatic event within the past year

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Interventional
• Phase: N/A
• Start date: 2024-12-01
• Primary completion: 2025-03-01
• Last update posted: 2026-04-22
• First posted: 2026-04-13

Sponsor & contact

Lead sponsor: Agri Ibrahim Cecen University (Other)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Introductory Information Form: (Baseline)
  This form was developed by the researchers based on the literature and includes questions on participants' sociodemographic characteristics.
• Brain Fog Scale (Baseline, After 4 weeks)
  This scale consists of 30 items and three subdimensions. The total score ranges from 30 to 150. The cognitive symptoms subscale ranges from 17 to 85, the physical symptoms subscale from 8 to 40, and the psychological symptoms subscale from 5 to 25. Higher scores on the total scale and/or subscales indicate greater levels of brain fog.
• Psychological Well-Being Scale (Baseline, After 4 weeks)
  Developed by Diener et al. and adapted into Turkish by Telef, this scale consists of eight items. The items assess components such as individuals' sense of competence, quality of relationships, and life evaluation. The scale contains no reverse-scored items and uses a 7-point Likert format ranging from 1 (strongly agree) to 7 (strongly disagree). The total score ranges from 8…
• Pittsburgh Sleep Quality Index (PSQI) (Baseline, After 4 weeks)
  The PSQI was developed in 1989, and its validity and reliability in Türkiye were established in 1996. It assesses sleep quality and disturbances over a one-month period. The index includes 24 items; however, item 19 and the last five items are used for clinical information only and are not included in scoring. The remaining 18 self-reported items evaluate seven components:…

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.